Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA-BCL6-1 first-in-human study of LY4584180 in previously treated B-cell lymphomas
jRCT2031260553Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of LY4584180 and rituximab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of dose-limiting toxicities and DLT-equivalent toxicities, Number of participants with one or more serious adverse events related to study drug administration and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
LY4584180rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT2031260553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260553.